More understanding is needed surrounding the normal and abnormal function of renal and urological tissue at a molecular and cellular level. Untargeted metabolomics can be applied to cultured cells, tissues from model organisms, and patient biopsies to discover metabolic drivers of processes such as cell death and malignant transformation. These insights can be translated into actionable biomarkers through follow-on targeted assays.

Metabolic diseases are inextricably linked. Therefore, understanding the relationship between urological diseases and other co-morbidities like diabetes, metabolic syndrome, and obesity will help to inform disease prevention, diagnosis and treatment. Metabolon’s deep experience in metabolomics at the level of large patient cohorts plays a vital role in future advancements in the renal and urological field.